Elizabeth Thompson, MD, discusses pediatric cancer, proton therapy, and her work as a peer reviewer for CURiE.
|Videos|December 25, 2017
Identifying Children With Leukemia Predisposition Syndromes
Author(s)Sharon A. Savage, MD
This video reviews classic syndromes associated with increased leukemia susceptibility and highlights pediatric patients who may be at increased risk for an inherited leukemia predisposition and should receive additional work-up.
Advertisement
In this video, Sharon A. Savage, MD, of the National Institutes of Health in Bethesda, Maryland, reviews classic syndromes associated with increased leukemia susceptibility and highlights pediatric patients who may be at increased risk for an inherited leukemia predisposition and should receive additional work-up.
Savage gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Advertisement
Related to this article
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
An end-of-phase 1 meeting was supported by phase 1b data showing efficacy with LYT-220 among relapsed/refractory myelodysplastic syndrome groups.
The updated NCCN guidelines for myeloproliferative neoplasms recommend rusfertide as a Category 1 option across both low- and high-risk polycythemia vera.
Jasmine Zain, MD, described how preexisting CHIP mutations should inform preinfusion risk counseling and treatment selection.
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
3
Acting on a HER2 Result and Navigating Access to Therapy
4
FDA Clears TriNav Advance for Expanded Liver Embolization Access
5